Table 4.

Demographic data of the subjects treated with cord blood-derived mesenchymal stromal cells (N = 40). The parameters marked with * are reported as median (range). GvHD, Graft-versus-Host Disease; NS, nephrotic syndrome; BPD, bronchopulmonary dysplasia.

Demographics
Female gender (N; %)	18; 42.8
Age (years) *	12 (0.5–60)
Subjects < 18 years of age (N; %)	33; 78.5
Weight (kg) *	42 (2.7–83.6)
Subjects ≥ 18 years of age *	57.1 (41.2–80)
Subjects < 18 years of age *	34.7 (2.7–83.6)
Disease (n of total subject; n of subjects > 18 years of age)
GvHD	8; 8
NS	33; 1
BPD	1; 0
Treatment
Cell dose (×106)/KG *	1.6 (1–10)
Cell dose (×106)/kg in subjects ≥ 18 years of age *	1.7 (1.4–3)
Intravenous administration (n)	41
Subjects who received 3 administrations (n; %)	30; 71.4
Interval between treatments (days) *	8 (3–42)